Dulaglutide lowers SBP and pulse pressure independent of weight reduction among diabetes patients
A new study published in Cardiovascular Diabetology suggests that in all of the placebo-controlled studies conducted as part of the AWARD program, dulaglutide 1.5 mg decreased systolic blood pressure (SBP) and pulse pressure in type 2 diabetes (T2D) patients.
Glucagon-like peptide-1 receptor agonists may lower blood pressure and reduce weight in type 2 diabetic patients. The main goal of this study, which was carried out by Keith Ferdinand and colleagues were to ascertain the effects of a 6-month therapy with dulaglutide 1.5 mg on patients with T2D that were weight-dependent and weight-independent.
To determine the weight-dependent (i.e., mediated by weight) and weight-independent effects of dulaglutide vs. placebo on change from baseline for systolic blood pressure, diastolic blood pressure (DBP), and pulse pressure, mediation analysis was performed for five randomized, placebo-controlled trials of dulaglutide 1.5 mg. These findings were merged using a random-effects meta-analysis. Mediation analysis was initially used in AWARD-11 to assess the weight-dependent and weight-independent impacts of dulaglutide 4.5 mg vs. 1.5 mg, then an indirect comparison with the mediation result for dulaglutide 1.5 mg vs. placebo was made. This investigation was done to determine if there was a dosage response between dulaglutide 4.5 mg and placebo.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.